[go: up one dir, main page]

CN114096533A - 一种三并环类化合物，包含其的药物组合物，其制备方法及其用途 - Google Patents

一种三并环类化合物，包含其的药物组合物，其制备方法及其用途 Download PDF

Info

Publication number
CN114096533A
CN114096533A CN202080050294.2A CN202080050294A CN114096533A CN 114096533 A CN114096533 A CN 114096533A CN 202080050294 A CN202080050294 A CN 202080050294A CN 114096533 A CN114096533 A CN 114096533A
Authority
CN
China
Prior art keywords
compound
formula
pharmaceutically acceptable
alkylene
acceptable form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080050294.2A
Other languages
English (en)
Other versions
CN114096533B (zh
Inventor
刘春池
唐建川
任云
刘金明
田强
宋宏梅
薛彤彤
王晶翼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of CN114096533A publication Critical patent/CN114096533A/zh
Application granted granted Critical
Publication of CN114096533B publication Critical patent/CN114096533B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

式I所示的三并环类化合物，包含其的药物组合物，以及其制备方法及其用途。所述化合物可以作为RORγ调节剂，具有抗肿瘤、抗自身免疫性疾病、抗炎等多种药理活性。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN202080050294.2A 2019-09-10 2020-08-31 一种三并环类化合物，包含其的药物组合物，其制备方法及其用途 Active CN114096533B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019108531270 2019-09-10
CN201910853127 2019-09-10
PCT/CN2020/112479 WO2021047406A1 (zh) 2019-09-10 2020-08-31 一种三并环类化合物，包含其的药物组合物，其制备方法及其用途

Publications (2)

Publication Number Publication Date
CN114096533A true CN114096533A (zh) 2022-02-25
CN114096533B CN114096533B (zh) 2024-03-08

Family

ID=74866087

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080050294.2A Active CN114096533B (zh) 2019-09-10 2020-08-31 一种三并环类化合物，包含其的药物组合物，其制备方法及其用途

Country Status (2)

Country Link
CN (1) CN114096533B (zh)
WO (1) WO2021047406A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202246266A (zh) * 2021-02-09 2022-12-01 大陸商北京加科思新藥研發有限公司 作為parp7抑制劑的三環衍生物

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032639A (en) * 1976-03-22 1977-06-28 American Home Products Corporation 2,3,4,4A-Tetrahydro-1H-pyrazino[1,2-a,]quinoxalin-5(6H)-ones and derivatives thereof for relieving hypertension
US20140088094A1 (en) * 2010-11-08 2014-03-27 Merck Sharp & Dohme Corp. N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
CN104530014A (zh) * 2013-12-25 2015-04-22 中国科学院广州生物医药与健康研究院 2-氧代-1,2-二氢苯并[cd]吲哚-6-磺酰胺类化合物及其组合物和应用
CN104812393A (zh) * 2012-05-08 2015-07-29 默沙东公司 用于抑制RORγ活性和治疗疾病的四氢萘啶和相关双环化合物
US20160304476A1 (en) * 2013-12-20 2016-10-20 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
CN107980042A (zh) * 2015-06-11 2018-05-01 莱斯拉公司 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物
US20180208587A1 (en) * 2014-05-05 2018-07-26 Lycera Corporation TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
CN108463458A (zh) * 2015-11-20 2018-08-28 生命医药公司 ROR-γ的调节剂
WO2020151232A1 (zh) * 2019-01-23 2020-07-30 上海和誉生物医药科技有限公司 1,2,3,4-四氢喹喔啉衍生物及其制备方法和应用

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032639A (en) * 1976-03-22 1977-06-28 American Home Products Corporation 2,3,4,4A-Tetrahydro-1H-pyrazino[1,2-a,]quinoxalin-5(6H)-ones and derivatives thereof for relieving hypertension
US20140088094A1 (en) * 2010-11-08 2014-03-27 Merck Sharp & Dohme Corp. N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
CN104812393A (zh) * 2012-05-08 2015-07-29 默沙东公司 用于抑制RORγ活性和治疗疾病的四氢萘啶和相关双环化合物
US20160304476A1 (en) * 2013-12-20 2016-10-20 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
CN104530014A (zh) * 2013-12-25 2015-04-22 中国科学院广州生物医药与健康研究院 2-氧代-1,2-二氢苯并[cd]吲哚-6-磺酰胺类化合物及其组合物和应用
US20180208587A1 (en) * 2014-05-05 2018-07-26 Lycera Corporation TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
CN107980042A (zh) * 2015-06-11 2018-05-01 莱斯拉公司 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物
CN108463458A (zh) * 2015-11-20 2018-08-28 生命医药公司 ROR-γ的调节剂
WO2020151232A1 (zh) * 2019-01-23 2020-07-30 上海和誉生物医药科技有限公司 1,2,3,4-四氢喹喔啉衍生物及其制备方法和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KRISHNANANDA SAMANTA，ET AL.: "A new synthesis of amino acid-based enantiomerically pure substituted 2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxalines", 《ORGANIC & BIOMOLECULAR CHEMISTRY》, vol. 2018, pages 2823 - 2828 *
薛晓纤 等: "孤儿核受体ＲOＲγ 拮抗剂的合成及其初步活性研究", 《中国药物化学杂志》, vol. 24, no. 4, pages 279 - 285 *

Also Published As

Publication number Publication date
WO2021047406A1 (zh) 2021-03-18
CN114096533B (zh) 2024-03-08

Similar Documents

Publication Publication Date Title
CN115667238B (zh) 一种五并五元环衍生物及其在医药上的应用
CN110582491A (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
CN118613478A (zh) Kif18a抑制剂
EP4206197A1 (en) Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method
JP6884800B2 (ja) メマンチン化合物及びその調整並びにその使用
KR20250022815A (ko) Hpk1 억제제 및 이의 의약품에서의 응용
CN118591535A (zh) 一种丙酸衍生物及其在医药上的应用
WO2018001332A1 (zh) 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途
CN114096533B (zh) 一种三并环类化合物，包含其的药物组合物，其制备方法及其用途
AU2019424628B2 (en) 1,2,3,4-tetrahydroquinoxaline derivative, preparation method therefor and application thereof
WO2024109922A1 (zh) 桥环并哒嗪类化合物及其用途
CN113666853B (zh) 可用作RORγ调节剂的联芳基类化合物
JP7406008B2 (ja) Ｃｄｋ９阻害剤としての多環式アミド系誘導体、その調製方法及び用途
CN107428682B (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
CN113666863A (zh) 可用作RORγ调节剂的联芳基类化合物
CN113773251A (zh) 可用作RORγ调节剂的苯胺类化合物
CN114096525B (zh) 联芳基类化合物，包含其的药物组合物，其制备方法及其用途
CN114502556B (zh) 一种联苯基氟代双键衍生物及其制备方法和在药学上的应用
CN114269753B (zh) 一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途
WO2024149340A1 (zh) 具有irak4抑制活性的吲哚酮衍生物及其制备方法和应用
WO2023165574A1 (zh) 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
WO2024179393A1 (zh) 亚砜酰亚胺化合物及其作为lrrk2蛋白激酶抑制剂的应用
WO2024131772A1 (zh) 具有sting抑制作用的含肟化合物及其药物组合物和用途
WO2023020416A1 (zh) 三环化合物、包含其的药物组合物及其用途
WO2025051180A1 (zh) 内酰胺类衍生物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant